S204or S. Given that SRS is minimally invasive, is able to treat lesions in surgically inaccessible locations, and is potentially more cost-effective than surgery, it is reasonable and more attractive alternative to surgery in the management of single brain metastasis. Prognostic variables in patients with brain metastases include KPS, number of brain metastases, and absence or presence of extra-cranial disease. Absence of extra-cranial disease, KPS > 70, and single (rather than multiple) metastasis in the brain usually predict longer survival. Patients who fulfill all these criteria will survive longer following SRS and will most likely benefit from the increased local control achieved by SRS. Survival in patients who do not meet any of these criteria is very poor in survival, and these patients are less likely benefit from SRS and should be treated with WBI alone. The Pros and Cons of each modality will be discussed at the conference.